Jiacheng Bi

11PUBLICATIONS
11CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Peripheral nervous system
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 24, 2026
Targeted inhibition of Nrf2 potentiates antitumor immunity and enhances the efficacy of immunotherapy in hepatocellular carcinoma.

Yan Zhu, Maoxuan Liu, Xiaokai Fan

|Nov 07, 2025
TRIM11 potentiates antitumor immunity via inhibition of the IFN-γ/PD-L1 axis.

Yingying Xu, Runjie Cai, Maoxuan Liu

|Sep 27, 2023
Suppression of protein quality control system by TRIM30a sensitises tumour cells to NK cell-mediated immune surveillance.

Lukman O Afolabi, Jiacheng Bi, Liang Chen

|Jan 19, 2022
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Xiaohu Zheng, Yaqi Wu, Jiacheng Bi

|Jan 13, 2022
NK cell dysfunction in patients with COVID-19.

Jiacheng Bi

|Sep 15, 2021
TIPE2 is a checkpoint of natural killer cell maturation and antitumor immunity.

Jiacheng Bi, Chen Cheng, Chaoyue Zheng

Pageof 2

Frequent Collaborators

2 joint publications

Zhigang Tian

2 joint publications

Xiaochun Wan

2 joint publications

Liang Chen

1 joint publications

Hua Wang